On July 10, ImmunityBio fell 5.58% in regular trading, trading at $8.34 USD/share, with Turnover of $12.05 million.

Within the Biotechnology sector where ImmunityBio belongs, the sector was broadly under pressure. Among individual stocks, Moderna down 7.61%, Ionis Pharmaceuticals down 7.42%, Argenx SE down 2.76%, AbbVie down 0.6%, Alnylam Pharmaceuticals up 0.16%.

ImmunityBio is a clinical-stage biotechnology company engaged in developing next-generation immune and cell therapies to enhance the natural immune system. Its core product Anktiva has been approved in 33 countries for the treatment of bladder cancer and lung cancer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)